Targeted therapy for scleroderma skin fibrosis Save

Date Added
October 2nd, 2017
PRO Number
Pro00070318
Researcher
Carol Feghali-bostwick
Keywords
Scleroderma
Summary

Patients with more severe forms of scleroderma skin disease will be recruited within 7 years of the onset of their scleroderma symptoms. Two, small skin biopsy samples will be obtained from these patients. These biopsies will be placed in a culture to allow them to grow and thrive. Typically, skin biopsy tissue from patients with scleroderma produce larger amounts of skin-thickening collagen. This extra collagen leads to a process known as fibrosis, which can be noticed by patients as thickening and hardening of the skin. Potential medications will be tested in these cultures to see if they reduce the amount of skin-thickening fibrosis produced by the skin tissue from these biopsies. The overall goal of this project is to identify potential medications that could be tested later for treatment of patients with scleroderma to reduce skin fibrosis.

Institution
MUSC
Recruitment Contact
Kelley Kajdasz
843-792-5920
gibsonke@musc.edu

Change_preferences

-- OR --

Create_login